Back to Search Start Over

Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer.

Authors :
Li, Xinyuan
Li, Kai
Li, Mengmeng
Lin, Xiaoyu
Mei, Yu
Huang, Xuemei
Yang, Huanjie
Source :
Frontiers in Oncology; 2/9/2022, Vol. 12, p1-12, 12p
Publication Year :
2022

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Gemcitabine is the most commonly used chemotherapy for the treatment of PDAC, but the development of drug resistance still remains challenging. Recently, exosomes have emerged as important mediators for intercellular communication. Exosomes affect recipient cells' behavior through the engulfed cargos, however the specific cargos responsible for gemcitabine resistance in PDAC are poorly understood. Here, we reported that exosomes could transfer gemcitabine resistance via a metalloproteinase 14 (MMP14)-dependent mechanism. MMP14 was identified as a major differentially secreted protein from the gemcitabine-resistant PDAC cells by comparative secretome. It was packaged into the exosomes and transmitted from the chemoresistant cells to the sensitive ones. The exosome-transferred MMP14 could enhance drug resistance and promotes the sphere-formation and migration abilities of the recipient sensitive PDAC cells. Mechanically, exosome-transferred MMP14 promotes the stability of CD44, the cancer stem cell marker in the recipient cells. Our results indicate that MMP14 is a key player for exosome-mediated transfer of gemcitabine resistance, thus targeting MMP14 in exosomes may represent a novel strategy to limit gemcitabine resistance in PDAC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2234943X
Volume :
12
Database :
Complementary Index
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
155187950
Full Text :
https://doi.org/10.3389/fonc.2022.844648